Bionomics Limited (BNO)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today Ľ it's FREE! Already a member? Login now!

General Information
Company Name: Bionomics Limited
Stock Code: BNO
GICS Sub-Industry: Biotechnology
Market Cap ($M): 203
Equiv. Shares (M): 418

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 0.485 $ 0.470 $ 0.515 $ 0.470 $ 0.470 1,244,551 $ 0.015  3.191 %

Current Broker Consensus Recommendation more
Recommendation: Buy (2)
Recommendation Date: 26th Feb 2015
Brokers Surveyed: 1

Company Overview

Business Description:
Bionomics Limited (BNO) is an Australian biotechnology company focused on the discovery and development of cancer, central nervous system disorders such as anxiety, depression and Alzheimer's Disease. BNO partners with pharmaceutical companies to get the drugs through the later stages of development and into the market.

Strategy Analysis:
BNO seeks to develop compounds to successful proof of concept in human clinical trials. The company is open to partnership at all stages of development. Additionally, BNO is open to in-licensing proposals that are in alignment with the company's overall therapeutic focus in cancer, inflammatory disorders and CNS diseases.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2016  F -- 9.9 -- 4.9 -- 0.0 --
2015  F -- -2.7 -- -- -- 0.0 --
2014  A 3.2 0.8 -- 79.8 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F
Bionomics (BNO) $196 M -- 6.3117 0.3108 61.0390 8.3481 6.3686 0.00 0.00 0.00
CSL (CSL) $42,869 M 0.0899 0.3357 0.0808 31.6659 23.7079 21.9361 1.33 1.76 2.01
Mesoblast (MSB) $1,358 M -- -- -- -- -- -- 0.00 0.00 0.00
Starpharma (SPL) $166 M -- -- -- -- -- -- 0.00 0.00 0.00
Sirtex Medical (SRX) $1,990 M 0.2906 0.5726 0.5050 85.2300 54.1955 36.0102 0.40 0.55 0.92

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
BNO 0.65 -- 4.52 -- 10.45
Market 1.00 14.2 1.02 1.16 2.83
Sector 0.82 17.1 2.63 1.18 7.73

Name Position Start Date
Dr Deborah Ann Rathjen Chief Executive Officer,Managing Director 21 June 2000
Mr Trevor Tappenden Non-Executive Director 15 September 2006
Dr Errol De Souza Non-Executive Director 28 February 2008
Dr Jonathan Lim Non-Executive Director 14 September 2012
Mr Graeme Kaufman Non-Executive Director,Non-Executive Chairman 18 September 2012

Name Position
Melanie Young Chief Financial Officer,Company Secretary
Jose Iglesias Chief Medical Officer
Emile Andriambeloson Head of Research, Neurofit
Peter Chu Vice President US Operations & Cancer Biology

Substantial Shareholders
Holding Name
21,642,425 (5.19%) Australian National University
24,241,071 (5.81%) John Leaver
24,000,000 (5.75%) Ausbil Dexia Limited
40,187,873 (9.63%) Link Traders (Aust) Pty Limited

Calendar of Events
Date Event
22 February 2016 Report (Interim)
09 October 2015 Report (Annual)
18 August 2015 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Investing in Property through Super

An educational booklet on running your own superannuation fund and investing in property.

More details...


Markets melt up

By Michael McCarthy (chief market strategist, CMC Markets) 19/12/2014 | Traders and investors caught short heading into the FOMC scrambled for cover in Europe and the US, in many cases driving indices to their best one day performance for 2015.

Aussie Investors take their foot off the accelerator

By Betty Lam (Sales Trader, CMC Markets) 18/12/2014 | Lead by the Fed-fervour offshore, Australians shares jumped on the Yellen cheer wagon. The material and energy stocks were back in vogue as both sectors gained over 3% in morning trade.

Fed Feeds Frenzy

By Michael McCarthy (chief market strategist, CMC Markets) 18/12/2014 | In spite of a frenzied pre-mortem, a benign statement from the US Federal Reserve‚Äôs Open Market Committee and steadying commodity markets drove investors back into share markets overnight. A calmer, stronger ruble helped offset European growth fears, highlighted in the overnight session by further declines in inflation.

Household brands Woolworths and Telstra Heavy Lifting

By Betty Lam (Sales Trader, CMC Markets) 11/12/2014 | Offshore jitters sent ripples through to Australian stocks. The open saw the local equities take 65 points off the index, catalysed by a mass-exit in energy stocks, yet again.

Steady open as Woodside investors wait on details of possible Wheatstone acquisition

By Ric Spooner (Chief Market Analyst, CMC Markets) 10/12/2014 | Yesterday‚Äôs news on Greek politics and China‚Äôs bond market came at a time when US and European stock markets have extended rallies and pushed valuations higher. This makes those markets vulnerable to downward corrections as profit takers act to avoid missing out.

MYEFO and Lima - December could be nasty.

BR Securities Australia Pty Ltd 2/12/2014 | December 2014 could go down as a nasty moment in Australian finance. MYEFO will reveal a deteriorating budget deficit and the UNFCCC meeting in Lima, Peru will provide the agreement, to be ratified in Paris in 2015, on how much (or little) CO2 is to be allowed into the atmosphere from 2020.


Sponsored Links